Seelos Therapeutics to Participate in Upcoming Investor Conference in September

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies. The company will host One on One meetings in New York, NY on Monday, September 23rd and Tuesday, September 24th.

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information: Anthony Marciano Head of Corporate Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park Ave., 12th Fl New York, NY 10022 (646) 293-2136 [email protected] www.seelostherapeutics.com https://twitter.com/seelostx https://www.linkedin.com/company/seelos

You May Also Be Interested In

• IN ADVANCE OF THE 25TH ANNIVERSARY OF THE ATTACKS ON 9/11, A NEW DOCUMENTARY UNCOVERS THE FORGOTTEN SCIENCE OF SWEAT DETOX: THE PROTOCOL THAT HELPED 9/11 SURVIVORS HEAL WHEN NOTHING ELSE WORKED
• Perma-Pipe Announces Closing of Global Credit Facility of Up to $139 Million
• Prime Drink Group Enters Into Strategic Partnership With Groupe Geloso to Accelerate the Expansion of Beach Day Every Day Across the Rest of Canada, the United States and Europe